Introduction
The Bio-Breeding (BB)' rat develops autoimmune diabetes similar to Type I human diabetes mellitus (1, 2) . The syndrome is characterized by sudden onset of hyperglycemia, ketonemia, and pancreatic beta cell destruction. Considerable evidence suggests that it has an autoimmune pathogenesis (1) (2) (3) . Pancreatic lymphocytic insulitis is present; the disease can be prevented by immunosuppression and immune enhancement. Islet autoantibodies are also present.
It is also possible to transfer the disease to nondiabetic rats using splenic lymphocytes from acutely diabetic rats (4) . The cells are cultured in the presence of concanavalin A (con A) and given intravenously to 30-35-d-old diabetes prone rats. Most rats become diabetic within 2 wk. Transfer to allogeneic histocompatible (RTlU) and RTIU X non-RTlu F1 hybrid rats is also possible if recipients are immunosuppressed (5, 6) , suggesting that the con A-activated cells constitute a cellular effector mechanism. The exact mechanisms by which spontaneous and induced BB rat diabetes occur remain unknown, and the present studies were undertaken to define the possible role of soluble factors in this process.
A preliminary account of this work has been presented in abstract form (Handler, E. S., J. P. Mordes, and A. A. Rats were housed under standard conditions, fed ad lib., and weighed and tested twice weekly. Diabetes was diagnosed on the basis ofglycosuria and a plasma glucose concentration >200 mg/dl. Equal numbers of male and female rats were used, and rat litters were randomly distributed into experimental and control groups.
Preparation ofconditioned media. Activated spleen cells for adoptive transfer of diabetes were prepared as previously described (4, 6) and injected intravenously into 30-35-d-old diabetes-prone BB/W rats at a dose of 40 X 10' cells. Supernates from cell cultures were collected, pooled, and stored at -300C. These acute diabetic spleen cell-conditioned media (ADSCM) were concentrated 10-fold using a 5-kD filter (YM5, Amicon Corp., Danvers, MA), passaged through a 0.45-itm filter (Nalge Co., Div. ofSybron Corp., Rochester, NY), and aliquots stored at -10C. Some ADSCM was fractionated by molecular weight using Amicon filters YM5, 10, 30, and 50. For use as control injections, media without cells were incubated for 72 h either with or without con A and similarly concentrated 10-fold.
Histology and lymphocyte subset analysis. Pancreata were fixed in Bouin's solution. Sections were stained with hematoxylin and eosin and evaluated for insulitis by a pathologist (Dr. Like) who was unaware of the treatment status ofthe animals. Lymphocyte counts and subset were determined using a fluorescence activated cell sorter as previously described (8). Histologically, the pancreata of all diabetic ADSCM-treated rats showed insulitis, end stage islets, severe pancreatitis, and peritonitis. Similar studies in rats given unconditioned media with or without con A and sacrificed at 60 d of age revealed mild peritonitis and pancreatitis but no insulitis. ADSCM treatment of nine diabetes-resistant W-line rats produced three diabetics (33%) within 3 wk ofthe first injection. Mean age at onset of diabetes was 51 d. The three diabetic Wline rats were not lymphopenic. Their peripheral white blood cell counts and differentials determined on tail vein blood averaged 12,367/mm3 with 80% mononuclear cells (principally lymphocytes), 17% polymorphonuclear cells, and 3% eosinophils. These values are similar to those of untreated W-line rats (n = 6) which averaged 13,000/mm3, 88% mononuclear cells, 10% polymorphonuclear cells, and 1% eosinophils. Splenic lymphocyte subset analysis of one diabetic W-line rat showed 20% OX8+ suppressor/cytotoxic cells and 26% W3/25+ helper cells, percentages comparable to those previously reported for nondiabetic W-line rats (9) .
Results
Media conditioned by con A-activated spleen cells from RT1U W-line, RT I WF, and RTlb BUF rats also accelerated the onset ofdiabetes in the RT IU diabetes-prone BB/W rat (Table II) . The time course, age at onset, and characteristics ofthe diabetic syndrome were similar to those observed with ADSCM injections. Table II also shows that injections of con A-activated spleen cells from nondiabetic major histocompatibility complex compatible or -incompatible spleen cells do not induce or accelerate diabetes.
We also tested ADSCM in intact (n = 15) and cyclophosphamide-treated (150 mg/kg, n = 4) immunosuppressed WF rats. None became diabetic. In addition, the administration of activated WF spleen cell-conditioned media to intact (n = 8) or cyclophosphamide immunosuppressed (n = 10) WF recipients failed to induce diabetes. Histologically, all had evidence ofmild pancreatitis and peritonitis but none had insulitis.
Discussion
These experiments suggest that a soluble factor in ADSCM accelerates diabetes in diabetes-prone BB/W rats and transfers it to resistant W-line rats. The lack ofdiabetogenicity in sonicated and irradiated (10) con A-treated cells suggests that there is little intracellular storage of the factor. The induction of diabetes in W-line rats suggests that lymphopenia may not be essential for the expression of diabetes as previously proposed (1 1). An inactive effector cell population may be present in W-line rats.
It is interesting to note that transfusions ofcertain cells protect against diabetes, (12) while a soluble factor obtained from the same cells can induce and accelerate the onset of the disease. One may speculate that viable transfused lymphocytes specifically enhance suppressor cell activity, perhaps by establishing a chimera. In contrast, a nonspecific factor may directly activate an effector cell specific to the BB rat, or, alternatively, reduce suppressor cell activity. Since control media, with and without con A, that were concentrated to the same extent as ADSCM failed to produce diabetes, it is unlikely that the active soluble factor is a nutrient constituent of media or of con A itself. In addition, accelerating activity was seen in ADSCM from which the mitogen had been removed using adsorbent (agarose-p-aminophenyl-a-D-mannopyranoside; P-L Biochemicals, Inc., Milwaukee, WI). The mechanism of action of ADSCM is not clear. Mitogenactivated spleen cells release many products, some of which are associated with lymphocyte growth and differentiation. Preliminary studies in our laboratory indicate that while interleukin-2 is present in ADSCM, injections of synthetic interleukin-2 do not affect the onset ofdiabetes in BB/W recipients (unpublished observations). It has been suggested that Ia antigens may be expressed on BB rat beta cells (13); if so, it could be that ADSCM induces such antigens. We have found, however, that ADSCM does not induce Ia antigens on rat insulinoma cells or rat macrophages (unpublished observations). The nature of the diabetogenic factor(s) produced by con A-activated spleen cells and their target cell populations in the BB/W rat remain to be determined.
